908 Devices Awarded $10.4M Order from the United States Air Force for its Handheld MX908 Device
24 Octobre 2023 - 10:30PM
Business Wire
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built
handheld and desktop devices for chemical and biochemical analysis,
announces today that it has been awarded a total of $10.4 million
in purchase orders from the United States Air Force and Air
National Guard Fire & Emergency Services Program for its MX908
handheld mass spectrometry device with Aero module.
Approximately a third of the orders include Aero module
upgrades, training, and support for existing MX908 devices
previously deployed to the Air National Guard. The Aero module
delivers additional capability to the MX908, enabling response
teams to quickly detect and identify aerosolized chemical threats,
such as Novichoks, pharmaceutical based agents and opioid
analogs.
With this award, the U.S. Air Force has broadened its adoption
of the MX908 device and Aero module to encompass both the Active
and Reserve components of the service, along with the Air National
Guard. These devices will now be stationed at over 130
installations, paving the way for enhanced emergency medical
response and hazardous materials operations.
The MX908 handheld device utilizes the company’s proprietary
High Pressure Mass Spectrometry (HPMS) technology to detect and
identify priority drugs, chemical agents, and explosives at trace
levels. The MX908 provides first responders with actionable
information when dealing with unknown threats, helping to ensure
public safety. For more information about 908 Devices and the
MX908, visit 908devices.com
About 908 Devices
908 Devices is revolutionizing chemical and biochemical analysis
with its simple handheld and desktop devices, addressing
critical-to-life applications. The Company’s devices are used at
the point-of-need to interrogate unknown and invisible materials
and provide quick, actionable answers to directly address some of
the most critical problems in life sciences research,
bioprocessing, pharma/biopharma, forensics and adjacent markets.
The Company is headquartered in the heart of Boston, where it
designs and manufactures innovative products that bring together
the power of mass spectrometry, microfluidic sampling and
separations, software automation, and machine learning.
Forward Looking Statements
This press release includes “forward looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements other than statements of historical facts are
forward-looking statements, including, without limitation,
statements regarding the expected uses and capabilities of the
Company’s products. Words such as “may,” “will,” “expect,” “plan,”
“anticipate,” “estimate,” “intend” and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. These forward-looking statements are based on
management’s current expectations and involve known and unknown
risks, uncertainties and assumptions which may cause actual results
to differ materially from any results expressed or implied by any
forward-looking statement, including the risks outlined under “Risk
Factors” and elsewhere in the Company’s filings with the Securities
and Exchange Commission which are available on the SEC's website at
www.sec.gov. Additional information will be made available in the
Company’s annual and quarterly reports and other filings that it
makes from time to time with the SEC. Although the Company believes
that the expectations reflected in its forward-looking statements
are reasonable, it cannot guarantee future results. The Company has
no obligation, and does not undertake any obligation, to update or
revise any forward-looking statement made in this press release to
reflect changes since the date of this press release, except as may
be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231024771935/en/
Media Contact: Barbara Russo brusso@908devices.com
Investor Contact: Carrie Mendivil IR@908devices.com
908 Devices (NASDAQ:MASS)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
908 Devices (NASDAQ:MASS)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025